AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Residents who returned to unburned homes after a 2021 wildfire near Boulder, Colorado often reported health issues months later, a study has found. Health Rounds: Health risks found in unburned ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

A diverse group of Baltimore startups poised for growth this year includes companies focused on climate prediction technology ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission. On a good day, your skin might be calm and glowy—but if you’re dealing with ...

Last September, the FDA approved Ebglyss for the treatment of eczema. With less frequent dosing, Ebglyss is expected to compete fiercely with Dupixent, a treatment that racked up over $13 billion in ...

Dupilumab is indicated for the treatment of asthma, atopic dermatitis (atopic eczema), nasal polyps (nasal polyposis). Dupixent is indicated for the treatment of adults and pediatrics patients aged 6 ...